[Skip to content]

Print this page
.

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-4041-6061-8081-100101-120; 121-140141-160161-180181-200201-220221-240241-260261-280; 281+

NICE TAs 141-160

 

REF

 

TITLE

 

DHFT Formulary link

East Midlands Cancer Network link (cancer drugs only)

TA141 

Rheumatoid arthritis (refractory) - abatacept (TA141) (replaced by TA195) 

Withdrawn

 

TA142

Anaemia (cancer-treatment induced) - erythropoietin (alfa and beta) and darbepoetin (TA142)

9.1.2 - 9.1.6 Megaloblastic, hypoplastic, haemolytic and renal anaemias: 9.1.3 Drugs used in hypoplastic, haemolytic and renal anaemias

 

TA143 

Ankylosing spondylitis - adalimumab, etanercept and infliximab (TA143)

10.1.2 - 10.1.3 Corticosteroids, rheumatic disease suppressants, gout

 

TA144 

Obesity - rimonabant (withdrawn) (TA144) (withdrawn)

Withdrawn 

 

TA145 

Head and neck cancer - cetuximab (TA145)

 

EMCN algorithm

DHFT protocol

TA146 

Psoriasis - adalimumab (TA146)

13.5.3 Drugs affecting the immune response

 

TA147

Breast cancer (advanced & metastatic) - bevacizumab (withdrawn) (TA147)  

Withdrawn

 

TA148

Lung cancer (non-small-cell) - bevacizumab (terminated appraisal) (TA148)

Withdrawn

 

TA149 

Glioma (recurrent) - carmustine implants (terminated appraisal) (TA149)

Withdrawn 

 

TA150

Colorectal cancer (metastatic) - cetuximab (terminated appraisal) (TA150) (replaced by TA242)

Withdrawn

 

TA151

Diabetes - insulin pump therapy (TA151)

6.1.1 - 6.1.2.3 Insulin, oral antidiabetic drugs, biguanides: 6.1.1.1 Short-acting Insulin 

 

TA152

Coronary artery disease - drug-eluting stents (TA152)

 

 

TA153

Hepatitis B - entecavir (TA153)   

5.3 Antiviral drugs: 5.3.3 Viral Hepatitis

 

TA154

Hepatitis B - telbivudine (TA154)

No drug implications

 

TA155

Macular degeneration (age-related) - ranibizumab and pegaptanib (TA155)

11.8 Miscellaneous ophthalmic preparations: 11.8.2 Ocular diagnostic and peri-operative preparations

 

TA156

Pregnancy (rhesus negative women) - routine anti-D (review) (TA156)

4.5 Drugs used in treatment of obesity  

 

TA157

Venous thromboembolism - dabigatran (TA157)

2.8 Anticoagulants: 2.8.2 Oral anticoagulants

 

TA158

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir (TA158)

5.3 Antiviral drugs: 5.3.4 Influenza

 

TA159

Pain (chronic neuropathic or ischaemic) - spinal cord stimulation (TA159)

No drug implications

 

TA160 

Osteoporosis - primary prevention (TA160)

6.6 Drugs affecting bone metabolism: 6.6.2 Bisphosphonates and other drugs affecting bone metabolism.